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Imbalance between the dopamine and serotonin
(5-HT) neurotransmitter systems has been implicated
in the comorbidity of Parkinson’s disease (PD) and
psychiatric disorders. L-DOPA, the leading treatment
of PD, facilitates the production and release of dopa-
mine. This study assessed the action of L-DOPA on
monoamine synaptic transmission inmouse brain sli-
ces.Applicationof L-DOPAaugmented theD2-recep-
tor-mediated inhibitory postsynaptic current (IPSC)
in dopamine neurons of the substantia nigra. This
augmentation was largely due to dopamine release
from 5-HT terminals. Selective optogenetic stimula-
tion of 5-HT terminals evoked dopamine release,
producing D2-receptor-mediated IPSCs following
treatment with L-DOPA. In the dorsal raphe, L-DOPA
produced a long-lasting depression of the 5-HT1A-
receptor-mediated IPSC in 5-HT neurons. When D2
receptors were expressed in the dorsal raphe, appli-
cation of L-DOPA resulted in a D2-receptor-mediated
IPSC. Thus, treatment with L-DOPA caused ectopic
dopamine release from 5-HT terminals and a loss of
5-HT-mediated synaptic transmission.
INTRODUCTION
The monoamine neurotransmitters, noradrenaline, dopamine,
and serotonin, modulate basic physiological functions including
sleep, motor control, food intake, sexual arousal, as well as
influence mood, temperament, and behavioral reinforcement.
Dysfunction of the dopamine system has been associated with
substance abuse, schizophrenia, attention-deficit hyperactivity
disorder, and Parkinson’s disease (PD). Imbalance in the seroto-
nin (5-hydroxytryptamine [5-HT]) system has been linked to the
etiology of complex emotional disorders including anxiety, bipo-
lar, impulsivity, and depression. The prevalence of comorbidity in
these disorders implicates significant interaction between the
dopamine and 5-HT systems. Understanding interactions be-
tween the monoamine systems is necessary to reduce side ef-
fects of pharmaceuticals that target these systems.944 Cell Reports 12, 944–954, August 11, 2015 ª2015 The AuthorsThe focus of this study is the immediate dopamine precursor
L-3,4-dihydroxyphenylalanine (L-DOPA), the leading therapy to
treat the motor symptoms of PD. Chronic L-DOPA treatment
produces undesirable side effects, including the development
of dyskinesias and fluctuations in mood that exacerbate psychi-
atric symptoms such as anxiety, impulsivity, and depression in
humans (Cools et al., 2003; Dama˜sio et al., 1971) and rodent
models (Borah and Mohanakumar, 2007; Eskow Jaunarajs
et al., 2012). Many studies have implicated an imbalance be-
tween dopamine and 5-HT as the cause of these detrimental
side effects (Borah and Mohanakumar, 2007; Carta et al.,
2007; Eskow Jaunarajs et al., 2012; Hornykiewicz, 1975; Nav-
ailles et al., 2010). There is also significant recent interest in using
L-DOPA to treat a myriad of health conditions, including Angel-
man syndrome, Tourette syndrome, restless legs syndrome,
subacute back pain, and cocaine dependence. Because these
conditions are often comorbid with 5-HT-linked psychiatric
symptoms, a greater understanding of the action of L-DOPA
on the serotonergic system is necessary.
5-HT neurons can convert L-DOPA to dopamine through the
L-amino acid decarboxylase (AADC; Arai et al., 1994; Ng et al.,
1970). Exposure of 5-HT neurons to L-DOPA results in vesicular
packaging of dopamine via the vesicular monoamine transporter
(VMAT2) and activity-dependent release of dopamine (Kannari
et al., 2000; Tanaka et al., 1999). Since VMAT2 preferentially
transports dopamine (Finn and Edwards, 1997), production of
dopamine in 5-HT neurons could reduce the content of vesicular
5-HT. But, the consequence of L-DOPA on 5-HT-dependent
synaptic transmission has not been reported. Furthermore, evi-
dence that 5-HT terminal-derived dopamine activates postsyn-
aptic dopamine receptors has not been described. The present
study describes a depression in serotonin synaptic transmission
after L-DOPA. The results reveal that following treatment with
L-DOPA serotonin terminals participate in D2-receptor-depen-
dent dopamine signaling in the substantia nigra (SN) and reduce
5-HT1A-receptor-dependent signaling in the dorsal raphe (DR).
RESULTS
Acute L-DOPA Enhances Dopamine Transmission in the
Substantia Nigra
In the SN, vesicular dopamine release elicits D2-receptor-
mediated inhibitory postsynaptic currents (IPSCs) through the
Figure 1. Acute L-DOPA in the SN Enhances Evoked and Sponta-
neous D2-IPSCs
(A) Representative trace of a whole-cell voltage-clamp recording of the out-
ward current induced by bath application of L-DOPA (10 mM), which was
reversed by the D2 receptor antagonist sulpiride (600 nM).
(B) Outward current to L-DOPA application, mean ± SEM (n = 23).
(C) Representative traces of D2-eIPSCs from a single experiment in ACSF and
after L-DOPA.
(D) D2-eIPSCswere evoked once every 50 s. L-DOPA increased the D2-eIPSC
amplitude, mean ± SEM, baseline: mean amplitude of six D2-eIPSCs pre-
ceding L-DOPA application (n = 22).
(E) Plot of spontaneous D2-sIPSC amplitude versus time from three experi-
ments (circle, square, and diamond) showing the increase in frequency by
L-DOPA.
(F) The frequency of D2-sIPSCs (per min, 5-min bins) increased during and
after L-DOPA application, mean ± SEM (n = 8–17, one-way ANOVA).
*p < 0.05 and **p < 0.01.activation of G protein-coupled inwardly rectifying potassium
(GIRK) channels (Beckstead et al., 2004). Whole-cell voltage-
clamp recordings were made from SN dopamine neurons in hor-
izontal midbrain slices from wild-type mice. A single electricalCstimulus was used to evoke D2-IPSCs (D2-eIPSC) once every
50 s in the presence of NMDA, AMPA, GABAA, GABAB, and
nACh receptor antagonists. As previously reported, application
of L-DOPA (10 mM, 10 min) had three actions (Beckstead et al.,
2004; Gantz et al., 2013; Mercuri et al., 1990). First, L-DOPA
(10 mM) produced an outward current (62 ± 6 pA, p < 0.001,
paired t test, Figures 1A, 1B, and 2A), which returned to baseline
upon wash out or was reversed by the D2 receptor antagonist,
sulpiride (600 nM). Pretreatment with sulpiride prevented the
outward current induced by L-DOPA (5 ± 3 pA, p = 0.22, n =
6). Second, L-DOPA produced a robust augmentation of the
D2-eIPSC amplitude (252% ± 19% of baseline, p < 0.001, paired
t test, Figures 1C, 1D, 2B, and 3C). Last, L-DOPA increased the
amplitude (p < 0.001, Mann-Whitney U test) and frequency of
spontaneous D2-sIPSCs (p = 0.02, one-way ANOVA, Figures
1E and 1F) that result from vesicular release of dopamine in the
absence of stimulation (Gantz et al., 2013). The transient outward
current produced by iontophoretically applied dopamine (I-DA)
was not increased by L-DOPA. In fact, there was a small
decrease in I-DA that correlated with the amplitude of the out-
ward current induced by L-DOPA (reduction in I-DA: 34 ±
11 pA; outward current: 45 ± 9 pA, p < 0.05, n = 9, Pearson cor-
relation). The results indicate that acute application of L-DOPA
enhanced evoked and spontaneous dopamine transmission in
the SN by a presynaptic mechanism.
The Conversion of L-DOPA to Dopamine Is Required
L-DOPA is converted to dopamine by the L-amino acid decar-
boxylase (AADC). To determine whether the conversion to dopa-
mine was required, brain slices were treated with the AADC
inhibitor, NSD-1015 (20 mM, >15 min). NSD-1015 blocked the
outward current induced by L-DOPA (NSD: 7 ± 3 pA, NSD and
L-DOPA: 0 ± 4 pA, p = 0.37, Figure 2A). In addition, NSD-1015
prevented the L-DOPA-induced enhancement in D2-eIPSC
amplitude (NSD: 18 ± 2 pA, NSD and L-DOPA: 16 ± 2 pA, p =
0.07, paired t test, Figure 2B), and the L-DOPA-induced increase
in spontaneous D2-sIPSC frequency (ACSF: 0.9 per min, NSD:
1.2 per min, NSD and L-DOPA: 0.8 per min, p = 0.27, Figure 2C).
Thus, the metabolism of L-DOPA to dopamine was required to
affect dopamine-dependent transmission.
5-HT Terminals Release Dopamine in the Substantia
Nigra after Acute or In Vivo L-DOPA
Dopamine neurons in the SN receive a prominent projection from
5-HT neurons in the raphe nuclei (Dray et al., 1976; Moukhles
et al., 1997). Given that 5-HT neurons can convert L-DOPA to
dopamine through the AADC (Arai et al., 1994), the ability of
5-HT terminals in the SN to participate in dopamine signaling af-
ter L-DOPA was assessed. 5-HT terminals, but not dopamine
neurons, have 5-HT1B/D receptors that strongly inhibit 5-HT
release (Cameron and Williams, 1994; Morikawa et al., 2000).
Application of the selective 5-HT1B/D receptor agonist, suma-
triptan (1 mM), alone had no effect on the D2-eIPSC (p = 0.77, Fig-
ures 3A and 3B), consistent with a previous report that used the
5-HT1 receptor agonist, 5-CT (Ford et al., 2006). However,
sumatriptan reduced and reversed the L-DOPA-induced
enhancement of the D2-eIPSC. Sumatriptan, when applied
before L-DOPA, significantly reduced the enhancement of theell Reports 12, 944–954, August 11, 2015 ª2015 The Authors 945
Figure 2. In the SN, the Conversion of L-DOPA to Dopamine Is Required
(A) Peak outward current to L-DOPA (10 mM) application, mean ± SEM (black circles, n = 23, paired t test). The AADC inhibitor, NSD-1015 (NSD, 20 mM, 15 min),
prevented the outward current induced by L-DOPA (open circles, n = 9, RM one-way ANOVA).
(B) D2-eIPSCs were evoked once every 50 s. NSD prevented the augmentation of D2-eIPSC by L-DOPA (black circles in ACSF, as shown in Figure 1D, open
circles in NSD, n = 13), mean ± SEM, baseline: mean amplitude of six D2-eIPSCs preceding L-DOPA application.
(C) NSD prevented the L-DOPA-induced increase in spontaneous D2-sIPSC frequency, mean ± SEM (per min, n = 11, RM one-way ANOVA).
ns, not significant and ***p < 0.001.D2-eIPSC by L-DOPA (136% ± 11% of baseline, p < 0.001, Fig-
ures 3C and 3D). When applied following L-DOPA, sumatriptan
decreased the D2-eIPSC to 142% ± 13% of its original ampli-
tude, which was not statistically different from the enhancement
by L-DOPA following pretreatment of sumatriptan (p = 0.79,
n = 9, unpaired t test). While sumatriptan markedly reduced the
L-DOPA-induced enhancement of the D2-eIPSC, the L-DOPA-
induced increase in the presence of sumatriptan was still signif-
icant (p = 0.001, paired t test, Figures 3A, 3C, and 3D). This
indicates that L-DOPA also increased dopamine release from
dopamine neurons. Furthermore, in the presence of sumatriptan,
L-DOPA increased the frequency of spontaneous D2-sIPSCs
(p < 0.001, Figure 3E), to the same extent and with a similar
time course as in control (p = 0.997, two-way ANOVA, Figures
1F and 3E, Gantz et al., 2013). Pretreatment with sumatriptan
also had no effect on the outward current produced by
L-DOPA (82.5 ± 10.5 pA, p = 0.53, n = 21, Mann-Whitney U
test). These results suggest that 5-HT terminals released dopa-
mine after acute exposure to L-DOPA.
To determine whether this phenomenon persists after chronic
L-DOPA treatment, mice were treated with L-DOPA (100 mg/kg,
subcutaneous) and a peripheral AADC inhibitor, benserazide
(200 mg/kg, subcutaneous), or with benserazide alone once
daily for 6 days. Brain slices were prepared 1 hr after the final in-
jection. D2-eIPSCswere evoked with a single stimulus (one stim)
or a train of five stimuli (five stims), to obtain better signal-to-
noise ratio (Figure 3F). In slices from mice treated with bensera-
zide alone, sumatriptan had no effect on theD2-eIPSC amplitude
(one stim: 94% ± 5%; five stims: 100% ± 5% of baseline, Fig-
ure 3G). In slices from mice treated with L-DOPA, however,
sumatriptan significantly decreased the D2-eIPSC amplitude,
whether evoked by one stim (67% ± 5% of baseline, p < 0.001)
or five stims (72% ± 5% of baseline, p < 0.001, Figures 3F and946 Cell Reports 12, 944–954, August 11, 2015 ª2015 The Authors3G). Taken together, these results demonstrate that dopamine
release in the SN, after acute or chronic in vivo L-DOPA expo-
sure, was attenuated by activation of 5-HT1B/D receptors, sug-
gesting that dopamine was released from 5-HT terminals.
An optogenetic strategy was employed to selectively activate
5-HT terminals in the SN, using the ePet-Cre transgenic mouse
line that expresses Cre recombinase in serotonin neurons (Scott
et al., 2005). The selective expression of Cre recombinase in
5-HT neurons in the ePet-Cre line was validated by immunohis-
tochemistry. ePet-Cre+/– mice were crossed with the Ai9 Cre
reporter mouse line that produces cytosolic tdTomato in Cre+
cells. Mice were transcardially perfused and the brains were
sectioned for immunohistochemistry (Figures S1A–S1C and
4A). No tdTomato+ cells were detected in ePet-Cre–/– sections.
In ePet-Cre+/– sections, cell counts (n = 4,330) were made in
the DR (Figure S1), which contains the majority of 5-HT neurons
in the rodent brain (Dahlstroem and Fuxe, 1964). Sections were
stained for tyrosine hydroxylase (TH) and tryptophan hydroxy-
lase (TpH), the rate-limiting enzymes in the production of dopa-
mine and 5-HT, respectively. In the DR, 82% of the Cre+ cells
were TpH+, whereas 7% of the Cre+ cells were TH+ and not
TpH+. Generally, the TH+ cells had smaller somas and were
located close to the cerebral aqueduct. The remaining Cre+ cells
(11%) did not co-stain with TpH or TH (Figure S1B). Last, 24% of
TpH+ neurons were not Cre+ (Figure S1C). In midbrain sections,
TpH+/Cre+ fibers were found throughout the SN, as well as Cre+-
only and TpH+-only fibers. Importantly, no SNdopamine neurons
(TH+) were Cre+ (Figure 4A).
The ePet-Cre+/– mice were crossed with the Ai32 mouse line
to express the light-activated cation channel, channelrhodop-
sin-2 (ChR2) in Cre+ cells. In slices from these mice, L-DOPA
augmented the electrically evoked D2-eIPSC to the same extent
as in slices from wild-type mice (244% ± 28%, p = 0.81, n = 10,
Figure 3. Activation of 5-HT Autoreceptors Attenuates the L-DOPA-
Induced Increase in Evoked D2-IPSCs in the SN
(A) Representative traces of D2-eIPSCs from a single experiment in ACSF,
after the addition of the 5-HT1B/D receptor agonist, sumatriptan (1 mM), and
after bath application of L-DOPA (10 mM) with sumatriptan.
(B) Sumatriptan alone did not change the D2-eIPSC amplitude (n = 21, paired
t test).
(C and D) D2-eIPSCs were evoked once every 50 s. Pretreatment with su-
matriptan significantly blunted the L-DOPA-induced increase in the D2-eIPSC
amplitude, compared to the increase in ACSF (ACSF: black circles, suma-
triptan: gray circles, n = 20–22, unpaired t test), mean ± SEM, baseline: mean
amplitude of six D2-eIPSCs preceding L-DOPA application.
(E) In the presence of sumatriptan, L-DOPA increased the frequency of
spontaneous D2-sIPSCs (per min, 5 min bins), mean ± SEM (n = 14–17, one-
way ANOVA).
(F and G) Sumatriptan decreased the D2-eIPSC amplitude following chronic
in vivo treatment with L-DOPA and a peripheral AADC inhibitor, benserazide
(bnz). (F) Representative traces of D2-eIPSCs evoked by a single (one stim)
or train (five stims) of electrical stimuli, in ACSF and after application of su-
matriptan. (G) Sumatriptan decreased the D2-eIPSC amplitude following
chronic in vivo L-DOPA and bnz treatment, but had no effect after bnz
treatment alone, mean ± SEM, baseline: mean amplitude of six D2-eIPSCs
Cunpaired t test). ChR2-expressing axon terminals were activated
with a light pulse (LED, 470 nm, 5–15 ms) every 50 s, in the pres-
ence of NMDA, AMPA, GABAA, GABAB, and nACh receptor an-
tagonists, and 4-aminopyridine (100 mM, see Supplemental
Experimental Procedures and Figure S2). In 16/18 recordings,
the activation of ChR2 had no effect prior to the application of
L-DOPA. In the other two recordings, activation of ChR2 evoked
an IPSC that was blocked by the 5-HT1A receptor antagonist,
WAY 100635 (100 nM). This observation is similar to previous
work done in slices from guinea pig, demonstrating a small pop-
ulation of dopamine neurons with 5-HT1A-receptor-mediated
inhibitory postsynaptic potentials (Cameron et al., 1997). After
treatment with L-DOPA (10 mM, 10 min), in every case, activation
of ChR2 induced a D2-receptor-mediated oIPSC (10 ± 1 pA, Fig-
ures 4B and 4C). The oIPSCs were completely eliminated by the
D2 receptor antagonist, sulpiride (600 nM, 1 ± 0.4 pA, p = 0.004,
n = 5, paired t test). The time-to-peak and duration of the D2-
oIPSC were longer than the D2-eIPSC, recorded in the same
conditions (time-to-peak: oIPSC: 389 ± 11 ms; eIPSC: 305 ±
14 ms; p < 0.001, Figure 4D; duration at 20%: oIPSC: 1,071 ±
83 ms, eIPSC: 795 ± 37 ms, p = 0.007, Mann-Whitney U test).
Activation of 5-HT1B/D receptors with sumatriptan or 5-CT
(100 nM) inhibited the D2-oIPSCs (80% ± 3% inhibition, p <
0.001, Figures 4B and 4C). Thus, after treatment with L-DOPA,
selective activation of 5-HT terminals in the SN evoked dopa-
mine release and produced a D2-receptor-mediated synaptic
current from 5-HT terminal-derived dopamine.
Acute L-DOPA Reduces Serotonin Transmission in the
Dorsal Raphe
To determine whether L-DOPA-induced synaptic release of
dopamine from 5-HT terminals affected vesicular 5-HT release,
recordings were made from 5-HT neurons in the DR. In the
DR, 5-HT release produces 5-HT1A-receptor-mediated IPSCs
through the activation of GIRK channels (Williams et al., 1988).
Whole-cell recordings were made from 5-HT neurons in coronal
DR slices from wild-type mice. 5-HT neurons were identified by
slow, broad, and regular action potential firing upon current in-
jection. 5-HT1A-eIPSCs were evoked by a single electrical stim-
ulus once every 50 s, in the presence of NMDA, AMPA, GABAA,
and a-1 adrenergic receptor antagonists. The 5-HT1A-eIPSC
was blocked by the 5-HT1A antagonist, WAY 100635 (100 nM),
or inhibited by activation of 5-HT1B/D receptors with sumatrip-
tan (1 mM). Application of L-DOPA (10 mM, 10 min) attenuated
the 5-HT1A-eIPSC amplitude (80% ± 6% of baseline, p =
0.002, Figure 5A), without changing the holding current (9 ±
4 pA, p = 0.06, n = 11, paired t test). Higher concentrations
of L-DOPA (30 and 50 mM) caused larger reductions in the
5-HT1A-eIPSC that did not recover upon L-DOPA wash out
(30 mM: 33% ± 7% of baseline, p < 0.001; 50 mM: 10% ± 2%
of baseline, p < 0.001, Figures 5A–5C and 5F).
In recordings from 5-HT neurons from the ePet-Cre+/–/Ai32+/–
mice, light stimulation (10 ms, LED, 470 nm) caused a depolari-
zation that elicited one to two action potentials (Figure S1D).preceding sumatriptan application. (n = 9–11, two-way RM ANOVAs). ns, not
significant.
*p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 4. Selective Activation of 5-HT Ter-
minals in the SN Elicits a D2-IPSC after
L-DOPA
(A) Representative maximum intensity projection
confocal image of dopamine neurons in the SN of
ePet-Cre+/–/Ai9+/– brain slices. Cre+ cells express
cytosolic tdTomato (tdTom, red). Sections were
immunostained for tyrosine hydroxylase (TH,
gray), labeling dopamine neurons, and tryptophan
hydroxylase (TpH, green), labeling 5-HT fibers.
Cre+ fibers colocalized with 5-HT fibers, and no
dopamine neurons were Cre+; scale bars, 25 mm.
(B and C) ChR2 activation in ePet-Cre+/–/Ai32+/–
midbrain slices (5–15 ms, 470 nm LED) did not
produce a current before application of L-DOPA.
With L-DOPA (10 mM), ChR2 activation evoked a
D2-oIPSC (n = 24) that was inhibited by 5-CT,
shown in (B) representative traces and (C) the
decrease in amplitude with 5-CT (100 nM) or su-
matriptan (1 mM) (n = 14, paired t test).
(D) The time-to-peak of the D2-eIPSC (electrically
evoked) was significantly faster than that of
the D2-oIPSC (optically evoked), mean ± SEM
(n = 11–24, unpaired t test).
***p < 0.001. See also Figures S1 and S2.ChR2 activation evoked a 5-HT1A-oIPSC (Figure 5D) that fol-
lowed the ChR2-induced inward current. 5-HT1A-IPSCs were
evoked once every 25 s, alternating between electrical and opti-
cal stimulation. Application of L-DOPA (30 mM, 10 min) signifi-
cantly attenuated the 5-HT1A-oIPSC (14% ± 6% of baseline,
p = 0.004, paired t test, Figures 5D and 5E), which did not recover
after a 20-min wash. The L-DOPA-induced attenuation in ampli-
tude and limited recovery of electrically or optically evoked syn-
aptic currents was indistinguishable (p = 0.73, two-way ANOVA,
Figure 5E). These results indicate a selective action of L-DOPA
on 5-HT terminals.
In PD patients, the level of L-DOPA in the cerebral spinal fluid
(CSF) fluctuates and varies considerably from patient to patient.
The concentration in the CSF varies from 130 nM up to 8 mM
and remains elevated for >1 hr following a single dose (Nyholm
et al., 2002; Olanow et al., 1991; Stocchi et al., 2005; Tohgi948 Cell Reports 12, 944–954, August 11, 2015 ª2015 The Authorset al., 1995). In the present study, pro-
longed application of a low concentration
of L-DOPA (1 mM, 50–65 min) resulted in
a significant reduction of the 5-HT1A-
eIPSC (48% ± 8% of baseline, p = 0.03,
paired t test, Figure S3). Thus, a clini-






The AADC inhibitor, NSD-1015 (20 mM,
>15 min) was used to determine whether
the conversion of L-DOPA to dopamine
was required. In slices exposed to NSD-1015, L-DOPA (30 mM) had no effect on the 5-HT1A-eIPSC
(NSD: 90 ± 17 pA, NSD and L-DOPA: 90 ± 17 pA, p > 0.05, Fig-
ure 5F). Therefore, the production of dopamine from L-DOPA
was required to affect 5-HT-dependent transmission. When
NSD-1015 was applied after L-DOPA (30 mM, 10 min), the ampli-
tude of the 5-HT1A-eIPSC remained depressed (recovery
following 10- to 15-min wash: ACSF: 36% ± 7% of baseline,
n = 7; NSD: 33% ± 3% of baseline, n = 4, p = 0.76, unpaired t
test). Thus, ongoing dopamine synthesis was not required after
L-DOPA wash out.
When 5-HT currents were evoked by photolysis of caged-
serotonin (I-5-HT, 5–25 ms, 365 nm), application of L-DOPA
(50 mM, 10 min) caused a modest reduction (81% ± 5% of base-
line, p < 0.05, Figures 6A and 6B) and a small outward current
(16 ± 3 pA, p < 0.001, Figures 6A and 6C). This postsynaptic
effect of L-DOPA was readily reversed with wash out, or the
Figure 5. Acute L-DOPA Reduces 5-HT1A-
IPSCs in the DR
(A) Concentration-dependent depression induced
by L-DOPA (10 min) in 5-HT1A-eIPSCs, mean ±
SEM, baseline: mean amplitude of six 5-HT1A-
eIPSCs preceding L-DOPA application (n = 15, 7,
and 10 for 10, 30, and 50 mM, respectively, paired
t tests).
(B) Representative traces of 5-HT1A-eIPSCs from
a single experiment in ACSF, after bath application
of L-DOPA (30 mM), and after a 20-min wash.
(C) 5-HT1A-eIPSCs were evoked once every 50 s.
L-DOPAsignificantly depressed the5-HT1A-eIPSC
with little recovery after wash, mean ± SEM (n = 7).
(D and E) In ePet-Cre+/–/Ai32+/– DR slices, 5-HT1A-
IPSCs were evoked once every 25 s, alternating
between electrical and optical stimulation. (D)
Representative traces of 5-HT1A-IPSC, evoked by
ChR2 activation (oIPSC). L-DOPA depressed
the 5-HT1A-oIPSC with little recovery in wash. (E)
L-DOPA-induced depression in the 5-HT1A-IPSC,
whetherelectrically evoked (eIPSC,black circles) or
optically evoked (oIPSC, open squares) was indis-
tinguishable, mean ± SEM (n = 7–8).
(F) Application of the AADC inhibitor, NSD-1015
(NSD, 20 mM, 15 min), prevented the depression
of the 5-HT1A-eIPSC by L-DOPA, mean ± SEM
(ACSF: black circles, n = 7; NSD: open circles,
n = 7, two-way RM ANOVA).
Baseline: mean amplitude of six 5-HT1A-IPSCs
preceding L-DOPA application; ns, not significant;
**p < 0.01 and ***p < 0.001. See also Figures S1
and S3.addition of NSD-1015 (20 mM, I-5-HT: 98% ± 6% of baseline, p <
0.001; outward current: 9 ± 4 pA, p < 0.001, Figures 6A–6C).
The results suggest that dopamine produced from L-DOPA
exerted a small, transient postsynaptic effect. Therefore, the
long-lasting L-DOPA-induced depression of 5-HT-mediated
synaptic transmission occurred primarily through a presynaptic
dopamine-dependent mechanism.
In the DR, 5-HT activates presynaptic 5-HT1B receptors that
inhibit further 5-HT release (Morikawa et al., 2000). To determine
whether L-DOPA or dopamine activates 5-HT1B receptors,
the effect of dopamine on the 5-HT1A-eIPSC was tested in
5-HT1B receptor knockout mice (5-HT1B KO) and their wild-
type (WT) littermates. Sumatriptan (1 mM) caused a marked inhi-
bition of the 5-HT1A-eIPSC in WTs (85% ± 5% inhibition) and
only a small inhibition in 5-HT1B KOs (34% ± 5% inhibition,
p < 0.001, Figure 6D). In slices from WT mice, dopamine
(10 mM, 10 min) inhibited the 5-HT1A-eIPSC (41% ± 5% of base-
line, p < 0.001, Figure 6E). The inhibition induced by dopamine
reversed after wash out (after 10- to 15-min wash: 98% ± 14%
of baseline, repeated-measures (RM) one-way ANOVA, Fig-
ure 6E). The transient action of dopamine was unlike the pro-
longed depression induced by L-DOPA. In slices from 5-HT1B
KO mice, dopamine inhibited the 5-HT1A-eIPSC (60% ± 6% of
baseline, p < 0.001) and recovered after wash out (after 10- to
15-min wash: 105% ± 7% of baseline, RM one-way ANOVA),
though the inhibition was slightly less than in WT slices (p =
0.02, unpaired t test, Figure 6E). The dopamine-induced reduc-
tion in the 5-HT1A-eIPSC also persisted in the presence of su-Cmatriptan (1 mM, 58% ± 7% of baseline, n = 5) in 5-HT1B KO
mice, indicating 5-HT1D receptors were not involved. In addi-
tion, dopamine (10 mM) decreased the 5-HT1A-oIPSC in slices
from ePet-Cre+/–/Ai32+/– mice (41% ± 5% of baseline, p =
0.009, n = 8, paired t test). L-DOPA (30 mM, 10 min) also pro-
duced similar inhibitions of the 5-HT1A-eIPSC in both WT and
5-HT1B KO mice that did not recover upon wash out (WT:
24% ± 3% of baseline; 5-HT1B KOmice: 28% ± 2% of baseline,
p = 0.31, unpaired t test, Figure 6F). Thus, the L-DOPA-induced
depression of the 5-HT1A-IPSC cannot be explained by action
on the 5-HT1B autoreceptor.
5-HT Neurons Release Dopamine in the Dorsal Raphe
after Acute L-DOPA
The ability of DR 5-HT neurons to package and release dopa-
mine after treatment with L-DOPA was examined through the
activation of virally expressed D2 receptors in the DR. Wild-
type mice received a midline injection of an adeno-associated
virus vector generating D2 receptor and GFP expression, as pre-
viously described (Neve et al., 2013). Infected neurons were
identified by visualization of GFP (Figure 7A). Electrical stimula-
tion (one or five stims) evoked IPSCs, in the presence of
NMDA, AMPA, GABAA, and a-1 adrenergic receptor antago-
nists. The resulting eIPSCs were inhibited by the 5-HT1A recep-
tor antagonist, WAY 100635 (100 nM, 88% ± 3% inhibition, p <
0.001, Figures 7B and 7C). In 7/12 recordings, the eIPSC was
not completely blocked by WAY 100635 (9 ± 2 pA). It is unclear
whether this WAY-resistant D2 component originates fromell Reports 12, 944–954, August 11, 2015 ª2015 The Authors 949
Figure 6. Dopamine Poorly Activates
5-HT1A and 5-HT1B Receptors
(A) Whole-cell voltage-clamp recording of the
5-HT1A-receptor-mediated currents induced by
photolysis of caged-serotonin once every 2 min
(I-5-HT, denoted by *) during bath application of
L-DOPA (50 mM). I-5-HT was blocked by WAY
100635 (10 mM).
(B) L-DOPA reduced I-5-HT and the reduction was
reversed with the addition of NSD-1015 (20 mM,
open circles) or wash out (filled circles), mean ±
SEM (n = 13, RM one-way ANOVA).
(C) L-DOPA induced an outward current that was
reversed with the addition of NSD-1015 or wash
out, mean ± SEM (n = 14, RM one-way ANOVA).
(D) Inhibition of the 5-HT1A-eIPSC by sumatriptan
(1 mM) was less in slices from 5-HT1B receptor KO
mice (5-HT1B KO) than from their wild-type litter-
mates (WT), mean ± SEM (n = 7–8, unpaired t test).
(E) Dopamine (10 mM) transiently inhibited the
5-HT1A-eIPSC in slices from WT (black circles,
n = 10) and 5-HT1B KO mice (open circles, n = 8),
mean ± SEM.
(F) L-DOPA (30 mM)-induced depression in the
5-HT1A-eIPSC was indistinguishable in slices
from 5-HT1B KO (open circles, n = 7) andWTmice
(black circles, n = 6), mean ± SEM.
Baseline: mean amplitude of three I-5-HTs or six
5-HT1A-IPSCs preceding L-DOPA application; ns,
not significant; *p < 0.05 and ***p < 0.001.dopamine release from local dopamine (TH+) neurons (Figures
S1A and S1B) or dopamine terminal projections (Pollak Dorocic
et al., 2014; Kitahama et al., 2000) or D2 receptor activation from
the release of noradrenaline (Onali et al., 1985; Yoshimura et al.,
1985). In the presence of WAY 100635, L-DOPA (10 mM, 10 min)
produced a transient outward current (69 ± 11 pA, p < 0.001, n =
12, paired t test, Figure 7B), and D2-receptor-mediated eIPSCs
that persisted long after the outward current recovered upon
wash out (29 ± 6 pA, p = 0.01, Figures 7B and 7D). 5-CT
(100 nM) significantly inhibited the L-DOPA-induced D2-eIPSCs
(65% ± 6% inhibition, p = 0.002, Figure 7E), indicating that most
of the dopamine was from 5-HT terminals. The D2 receptor
antagonist, sulpiride (600 nM) completely abolished the D2-
eIPSC (1 ± 0.3 pA, p < 0.001, Figure 7F). Disruption of the vesic-
ular monoamine transporter with reserpine (1 mM, 1 h) abolished
the 5-HT1A-eIPSC (4% ± 0.3% of baseline, p = 0.005, n = 3,
paired t test, see also Pan et al., 1989). After reserpine,
L-DOPA still produced an outward current (61 ± 22 pA, n = 4).
However, pretreatment with reserpine completely prevented
the L-DOPA-induced D2-eIPSC (in WAY and reserpine: 2 ±
0.6 pA; in WAY, reserpine, and L-DOPA: 1 ± 0.5 pA, p = 0.15,
n = 6, paired t test). Thus, viral-mediated expression of D2
receptors in 5-HT neurons revealed that treatment with
L-DOPA resulted in dopamine release by a vesicularmechanism.
The time course of dopamine release mirrored that of the
depression of the 5-HT1A-IPSC.
DISCUSSION
The ability of 5-HT terminals to convert and release dopamine af-
ter L-DOPA was first described 45 years ago (Ng et al., 1970).950 Cell Reports 12, 944–954, August 11, 2015 ª2015 The AuthorsDespite this, the ability of 5-HT terminal-derived dopamine to
activate postsynaptic dopamine receptors or the inhibition of se-
rotonin transmission by displacement with dopamine has not
been reported. This study assessed the action of L-DOPA on
monoamine synaptic transmission on dopamine neurons in the
SN and 5-HT neurons in the DR. The results reveal that treatment
with L-DOPA causes ectopic dopamine release from 5-HT
terminals and a simultaneous loss of 5-HT-mediated synaptic
transmission.
Ectopic Release of Dopamine from 5-HT Terminals
Numerous studies have demonstrated that 5-HT terminals can
convert L-DOPA to dopamine that is then packaged into vesicles
and released in an activity-dependent manner (Arai et al., 1994;
Kannari et al., 2000; Ng et al., 1970; Tanaka et al., 1999). How-
ever, the majority of studies isolated 5-HT terminals by first
ablating nigrostriatal dopamine neurons. By preserving the ni-
grostriatal dopamine neurons, this study assessed the ability of
5-HT terminals to release dopamine, activate postsynaptic D2
receptors, and otherwise mimic dopamine-dependent synaptic
transmission.
In the SN, dopamine is released from the somatodendritic
compartment spontaneously and after electrical stimulation to
produce D2-IPSCs (Beckstead et al., 2004; Gantz et al., 2013).
This study found that L-DOPA increased dopamine release
from dopamine neurons, augmenting D2-IPSCs. These dopa-
mine neurons also receive projections from the 5-HT neurons
in the raphe nuclei (Dray et al., 1976; Moukhles et al., 1997).
The release of dopamine from 5-HT terminals after L-DOPA
was demonstrated using pharmacological and optogenetic
experiments. The terminals of 5-HT neurons have 5-HT1B/D
Figure 7. Virally Expressed D2 Receptors in
the DR Mediate D2-IPSCs after L-DOPA
(A) Representative maximum intensity projection
confocal image of GFP+ neurons in the DR (ventral
to the cerebral aqueduct, aq.) infected with AAV-
D2; scale bar, 50 mm.
(B–F) Representative traces from a single
experiment.
(B) Whole-cell voltage-clamp recording of the
outward current and D2-eIPSCs induced by bath
application of L-DOPA (10 mM), in the presence of
WAY 100635 (100 nM). eIPSCs were evoked by
electrical stimulation (arrow, one or five stims)
once every 50 s, stimulation artifacts were blanked
for clarity.
(C) eIPSCs in ACSF and after WAY 100635.
5-HT1A-eIPSCs were inhibited by WAY 100635
(n = 12, paired t test).
(D) D2-eIPSCs in WAY 100635 and after L-DOPA
in the continued presence of WAY 100635.
L-DOPA augmented the D2-eIPSC (n = 18, paired
t test).
(E) L-DOPA-induced D2-eIPSCs in WAY 100635
and after 5-CT (100 nM). D2-eIPSCswere inhibited
by 5-CT (n = 11, paired t test).
(F) L-DOPA-induced D2-eIPSCs in WAY 100635
and after sulpiride (600 nM). Sulpiride completely
eliminated the D2-eIPSCs (n = 12, paired t test).
*p < 0.05, **p < 0.01, and ***p < 0.001.receptors, which inhibit transmitter release (Cameron and Wil-
liams, 1994; Morikawa et al., 2000). Under control conditions,
the activation of these receptors did not alter the amplitude of
the D2-eIPSC. However, after acute L-DOPA application, acti-
vating 5-HT1B/D receptors decreased the D2-eIPSC. In addi-
tion, following 6 days of in vivo L-DOPA treatment, activation
of 5-HT1B/D receptors inhibited the D2-eIPSC. Last, following
L-DOPA, selective stimulation of ChR2-expressing 5-HT axon
terminals found throughout the SN evoked dopamine release re-
sulting in a D2-receptor-mediated IPSC. Thus, acute and in vivo
treatment with L-DOPA produced dopamine release from 5-HT
terminals in the SN.
Taken together, this study made three observations related to
the ability of 5-HT terminals to mimic dopamine synaptic trans-
mission after treatment with L-DOPA: (1) 5-HT terminals in the
SN are positioned such that the release of dopamine activates
D2 receptors on dopamine neurons; (2) 5-HT terminal-derived
dopamine does not likely contribute to spontaneous D2-recep-
tor-mediated synaptic transmission; and (3) the release of newly
synthesized dopamine from 5-HT terminals is greater and per-
sists for longer than the release from dopamine neurons.Cell Reports 12, 944–954The projections of 5-HT neurons are
widespread, including the prefrontal cor-
tex, hippocampus, and nucleus accum-
bens, and form somatic, dendritic, and
axonal contacts in these areas (Milner
and Veznedaroglu, 1993; Van Bockstaele
et al., 1993). An in vivo microdialysis
study, using a rodent model of PD, found
that dopamine levels were increased inthese regions following an intraperitoneal injection of L-DOPA,
and destruction of 5-HT neurons attenuated the L-DOPA-
induced increase in dopamine (Navailles et al., 2010). As found
in the present study in the SN, dopamine receptors in each of
these projection areas could be activated by dopamine from
5-HT terminals.
Depression of 5-HT-Mediated Synaptic Currents
by L-DOPA
Reduced 5-HT levels and altered 5-HT metabolism are often re-
ported in PD patients (reviewed in Eskow Jaunarajs et al., 2011)
and rodentmodels of PD treatedwith L-DOPA (Borah andMoha-
nakumar, 2007; Navailles et al., 2011; Ng et al., 1970; Stansley
and Yamamoto, 2014). However, the impact of L-DOPA on
5-HT-receptor-mediated signaling had yet to be examined.
The present study describes a long-lasting L-DOPA-depen-
dent depression of 5-HT1A-receptor-mediated IPSCs in 5-HT
neurons in the DR. The decrease in 5-HT transmission resulted
from the production and packaging of dopamine into vesicles.
This most likely resulted from displacement of vesicular 5-HT,
since VMAT2 transports dopamine more efficiently than, August 11, 2015 ª2015 The Authors 951
serotonin (Finn and Edwards, 1997). Inhibition of the AADC pre-
vented the L-DOPA-induced depression in the 5-HT1A-eIPSC,
demonstrating the synthesis of dopamine was required. Finally,
with the expression of D2 receptors in the DR, L-DOPA resulted
in D2-receptor-mediated IPSCs. Inhibition of VMAT2 disrupted
the loading of dopamine into vesicles and completely prevented
the D2-eIPSCs. Therefore, the D2-eIPSCs were due to vesicular
release of dopamine from 5-HT terminals. The ectopic release of
dopamine from 5-HT terminals is likely dysregulated, since
exogenous application of dopamine had little effect on 5-HT1B
autoreceptors. However, dopamine caused a transient inhibition
of the 5-HT1A-IPSC that was not explained fully by action on
the 5-HT1A and 5-HT1B/D receptors, suggesting another mech-
anism by which dopamine may inhibit release from 5-HT
terminals. It is possible that 5-HT terminal-derived dopamine
contributes to the depression of the 5-HT1A-IPSC through this
dopamine-mediated inhibition. Taken together, this study dem-
onstrates that after L-DOPA, dopamine is released from 5-HT
neurons impairing 5-HT-mediated synaptic transmission.
The significance of these results likely extends beyond the
depression of the 5-HT1A-eIPSC in the DR. The projections of
5-HT neurons will be affected similarly (To¨rk, 1990). 5-HT can
activate as many as 14 distinct 5-HT receptors, influencing mul-
tiple effectors and modulating the release of glutamate, GABA,
acetylcholine, in addition to monoamine neurotransmitters (re-
viewed in Fink and Go¨thert, 2007). Thus, the reduction in 5-HT
release will have widespread actions throughout the CNS.
Implications for the Experimental and Clinical Use of
L-DOPA
This study demonstrates that after treatment with L-DOPA, 5-HT
terminals participate in dopamine signaling at the expense of
5-HT synaptic transmission. These actions were observed with
clinically relevant concentrations of L-DOPA and without abla-
tion of dopamine neurons. Therefore, the participation of 5-HT
terminals in dopamine releasemust be considered during exper-
imental and clinical use of L-DOPA.
In advanced PD with substantial dopamine denervation, the
release of dopamine from 5-HT terminals in the forebrain is
thought to be beneficial, but the ectopic release has been sug-
gested to be more detrimental than therapeutic, particularly to
affective symptoms (Borah and Mohanakumar, 2007; Carta
et al., 2007; Eskow Jaunarajs et al., 2012; Hornykiewicz, 1975).
Thus, in the context of PD treatment, this study provides a
cellular and synaptic basis for testing pharmaceuticals that re-
cruit 5-HT neurons to synthesize and release dopamine while
sparing 5-HT-receptor-mediated signaling. In addition to PD,
there is substantial recent interest in L-DOPA treatment for other
health conditions, including Angelman syndrome, Tourette syn-
drome, and cocaine dependence. These conditions are often co-
morbid with affective disorders, notably impulsivity (Belin et al.,
2008; Ersche et al., 2010; Palumbo and Kurlan, 2007; Pelc
et al., 2008), as seen in PD patients treated with L-DOPA (Cools
et al., 2003). Impulse control is influenced by 5-HT neurons in the
dorsal raphe, where reduced 5-HT levels promote impulsive
behavior (Fonseca et al., 2015; Miyazaki et al., 2014). Thus, a
greater understanding of the action of L-DOPA on the serotonin
system is necessary when considering its use when certain af-952 Cell Reports 12, 944–954, August 11, 2015 ª2015 The Authorsfective symptoms are also present. Indeed, in PD patients and
animal models, combination therapies with L-DOPA, 5-HT1A,
and 5-HT1B receptor agonists have proved effective in treating
dyskinesias and psychiatric symptoms, such as depression
and anxiety (Mun˜oz et al., 2008 and reviewed in Shimizu and
Ohno, 2013).
Concluding Remarks
Taken together, this study demonstrates L-DOPA is driving
ectopic dopamine release from 5-HT neurons. Dopamine
derived from 5-HT terminals can activate D2 receptors in the
SN and mediate inhibitory postsynaptic currents. However, in
5-HT neurons, newly synthesized dopamine is transported into
vesicles, where it ultimately impairs 5-HT-mediated synaptic
transmission in the DR. Thus, L-DOPA generates an imbalance
between the dopamine and 5-HT neurotransmitter systems.
Given the extensive projections of each system, such an imbal-
ance will have widespread consequences throughout the CNS.
EXPERIMENTAL PROCEDURES
Animals
All studies were conducted in accordance with the Institutional Animal Care
and Use Committee at Oregon Health and Science University. All mice were
group-housed in standard plastic containers on a 12-hr-light/dark cycle,
with food and water available ad libitum. Male and female wild-type
(C57BL/6) mice (>30 days old) were used, and principal results (Figures 1, 2,
3, and 5) were repeated in DBA/2J mice. Treated mice received a once-daily
subcutaneous injection of L-DOPA methyl ester (100 mg/kg) and benserazide
(200 mg/kg) dissolved in saline, or an equal volume of benserazide only
(200 mg/kg), for 6 days and were killed 1 hr after the last injection. ePet-
Cre+/– mice on a C57BL/6 background were obtained from The Jackson Lab
(stock no. 012712). Ai9 and Ai32 mice (stock no. 007905 and 012569, respec-
tively), backcrossed onto C57BL/6 background, were kindly provided by
Dr. Tianyi Mao (Vollum Institute). 5-HT1B receptor knockout mice, maintained
on a BALB/c background, were kindly provided Dr. Mark Pennesi (Casey Eye
Institute).
Stereotaxic Virus Injection
D2 receptors were ubiquitously expressed in the DR using an adeno-associ-
ated virus (AAV) vector (AAV9 D2-IRES-GFP; Virovek) encoding a mixture of
short and long splice variants of the rat D2 receptor (Neve et al., 2013). Mice
were injected when 5–7 weeks old. Mice were immobilized in a stereotaxic
alignment system under isoflurane anesthesia and received one midline injec-
tion, 500 nl delivered over 5 min. The coordinates for injection were (with
respect to bregma) AP3.9mm,ML 0.0mm, DV2.8mm. Animals recovered
for 4–5 weeks to allow for expression. Infected neurons were identified in the
slice by visualization of GFP.
Slice Preparation and Electrophysiology
Detailed procedures and recipes for slice preparation and electrophysiology
can be found in Supplemental Experimental Procedures. Briefly, horizontal
mouse midbrain or coronal dorsal raphe (DR) slices were obtained using a
vibrating microtome (Leica) and incubated in modified Krebs’ buffer solution,
at 30C in vials with 95%/5% O2/CO2 saline with MK-801 (10 mM) for
>30 min prior to recording. Dopamine neurons of the substantia nigra pars
compacta (SN), and 5-HT neurons in the DR were identified by their location
and physiological characteristics. Whole-cell voltage-clamp recordings were
made with a K-methanesulfonate-based internal solution containing BAPTA
(10 mM). Transmitter release was evoked electrically or in ePet-Cre+/–/
Ai32+/– slices with a 470-nm LED pulse. Currents were isolated pharmacolog-
ically, with AMPA, GABAA, a-1 adrenergic (DR only), GABAB (SN only), nACh
(SN only) receptor antagonists. Currents peaks were determined by averaging
the current ±20 ms from the greatest upward deflection. For each cell,
three to 12 consecutive currents were averaged to determine amplitude,
time-to-peak, and duration at 20% of the peak. sIPSCs were detected as pre-
viously described (Gantz et al., 2013). Data were acquired using AxoGraph
software (AxographX) and LabChart 7 (AD Instruments) and were post hoc
filtered.
Immunohistochemistry
Mice were anesthetized with Avertin (i.p.) and transcardially perfused with 5%
sucrose in H2O followed by ice-cold 4% paraformaldehyde in PBS (pH 7.4).
Brains were fixed overnight at 4C and then sliced coronally (DR) and horizon-
tally (SN) in 60-mm sections. Free-floating slices were permeabilized in PBS
with 0.3% Triton-X (PBS-T) then blocked in PBS-T with 0.5% fish skin gelatin
for 1 hr. Slices from ePet-Cre+/– /Ai9+/– mice were incubated 24 hr at 24C in
mouse anti-TH (1:1,000) primary antibody. Slices were washed then incubated
in Alexa-Fluor-647-conjugated goat anti-mouse secondary antibody (1:1,000)
for 3 hr. Slices were washed then incubated for 48 hr at 24C in rabbit anti-TpH
primary antibody (1:500). Following washing, slices were incubated in Alexa-
Fluor-488-conjugated goat anti-rabbit secondary antibody (1:1,000) for 3 hr.
Slices from AAV-D2-infected wild-type mice were incubated in rabbit anti-
GFP conjugated to Alexa Fluor 488 (1:1,000) 24 hr at 4C. Washed slices
were mounted with Fluoromount (Sigma) aqueous mounting medium.
Confocal images were collected on a Zeiss LSM 780 microscope with a 203
(0.8 NA) or 403 water-immersion lens (1.2 NA) and processed using Fiji.
Materials
CGP 55845, 5-CT, WAY 100635, and NPEC-caged-serotonin were obtained
from Tocris Bioscience. MK-801 was obtained from Abcam. Sumatriptan
was from Glaxo Wellcome Research and Development. All other drugs were
obtained from Sigma-Aldrich.
Data Analysis
Values are given as means ± SEM. Unless otherwise noted, n = number of
cells. All data sets with n > 10 were tested for normality with Shapiro-Wilk
normality test. Nonparametric statistics were used if any data set failed a
normality test and was skewed. Significant differences in within-group com-
parisons were determined for two group comparisons by paired two-tailed
t tests or two-tailed Mann Whitney U tests, and in more than two group com-
parisons by one- or two-way repeated-measures (RM) ANOVA. Significant
mean differences in between-group comparisons were determined by un-
paired two-tailed t tests, or by one- or two-way ANOVAs. ANOVAs were
followed, when appropriate (p < 0.05) by Bonferroni’s multiple comparisons
post hoc tests. Correlations were determined by two-tailed Pearson Corre-
lation test. Statistical analysis was performed using GraphPad Prism 6
(GraphPad).
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